Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto
Ann Oncol. 2025 Feb;36(2):221-222.
doi: 10.1016/j.annonc.2024.10.011.
Epub 2024 Nov 8.
1 Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: efelip@vhio.net.
2 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
3 City of Hope National Medical Center, Duarte, USA.
4 Janssen Research & Development, Spring House, USA.
5 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.